Stock Screener App

Frei -

Installieren

3.67

3.55% -0.135

after-market

Handel nachbörslich: 3.67

Titan Pharmaceuticals Inc De (TTNP)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Titan Pharmaceuticals Inc De Aktie (TTNP) Neueste Nachrichten

Elite Pharmaceuticals Revenue Surges 33% to $18.9M, Operating Profit Jumps 84% | ELTP Stock News - StockTitan

Meiji Seika Pharma Invests in ARCALIS to Boost Japan's mRNA Vaccine Production | ARCT Stock News - StockTitan

Virpax Pharmaceuticals Raises $5M in Public Offering to Advance Pain Management Drug | VRPX Stock News - StockTitan

Universe Pharmaceuticals Announces 15:1 Reverse Stock Split Amid NASDAQ Concerns | UPC Stock News - StockTitan

Acurx Pharma Q3: New Patent Win & Trial Progress Despite Cash Decline to $5.8M | ACXP Stock News - StockTitan

Syros Pharma Stock Alert: Phase 3 Trial Fails, Loan Default Triggered | SYRS Stock News - StockTitan

Longboard Pharma Launches Groundbreaking Phase 3 Trial for Rare Epilepsy Treatment | LBPH Stock News - StockTitan

CERo's Cancer Drug Shows Breakthrough: Kills Ovarian Cancer Without Toxicity in Key Study | CERO Stock News - StockTitan

Hepion & Pharma Two B Merger Advances: SEC Approves Key Registration for $HEPA Deal | HEPA Stock News - StockTitan

NRx Pharmaceuticals Sets Q3 2024 Earnings Call for November 14 | NRXP Stock News - StockTitan

NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results - StockTitan

Ionis Pharmaceuticals to Present at 6 Major Healthcare Investor Conferences | IONS Stock News - StockTitan

Elite Pharmaceuticals (ELTP) to Host Q2 FY2025 Earnings Call on November 15 | ELTP Stock News - StockTitan

Madrigal Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | MDGL Stock News - StockTitan

Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024 - StockTitan

InMed Gets Nasdaq Lifeline: 20:1 Share Consolidation Plan to Avoid Delisting | INM Stock News - StockTitan

Bionoid Pharma Unveils 5-Year AI-Powered Growth Strategy, Targets 15% EBITDA | BINP Stock News - StockTitan

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan

Dario Expands Pharma Collaborations with Global Pharma Leader to Enhance User Engagement - StockTitan

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes - StockTitan

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - StockTitan

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - StockTitan

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics - StockTitan

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - StockTitan

Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024 - StockTitan

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary - StockTitan

Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call - StockTitan

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives - StockTitan

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024 - StockTitan

Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results - StockTitan

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 - StockTitan

KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) - StockTitan

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024 - StockTitan

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences - StockTitan

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024 - StockTitan

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - StockTitan

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe - StockTitan

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. - StockTitan

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 - StockTitan

Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform - StockTitan

New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support - StockTitan

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. - StockTitan

Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share - StockTitan

Opioids Agonist Drugs Market Research Report 2024 -Purdue Pharma, Titan pharmaceuticals, Boehringer Ingelheim, Janssen P – IndiaPolitics.com - IndiaPolitics.com

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder - StockTitan

Elite Pharmaceuticals' Generic Adderall(R) Receives Marketing Approval from the Israeli Ministry of Health - StockTitan

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment - StockTitan

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 - StockTitan

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - StockTitan

Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting - StockTitan

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - StockTitan

Joint Venture Company Established for Incubation of Early Drug Discovery Programs; Investment from Takeda, Astellas and Sumitomo Mitsui Banking - StockTitan

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - StockTitan

Rhythm Pharmaceuticals Announces New Employment Inducement Grants - StockTitan

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC - StockTitan

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency - StockTitan

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - StockTitan

SMMT

$18.98

3.66%

INCY

$76.97

1.45%

MRNA

$39.51

7.22%

UTHR

$359.21

1.11%

BGNE

$187.69

0.81%

BNTX

$101.87

2.16%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters